Onartuzumab

Research use only, not for human use.

Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.

Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity.

Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET.Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines.

Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth.Animal Model:Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells Dosage:30 mg/kg Administration:IP, twice a week for 2 mouth Result:Suppressed tumor growth, but did not affect the mean in vivo human HGF levels.Animal Model:U-87 MG tumor-bearing mice Dosage:30 mg/kg Administration:IP, once Result:Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).

——

Angiogenesis

c-Met/HGFR

c-Met/HGFR

——

——

1133766-06-9

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years